Soon after the identification of germline LKB1 mutations in PJS, LKB1 somatic mutations were detected as associated with poor survival of patients with sporadic malignancies, such as non-small cell lung cancer (NSCLC), breast cancer, pancreatic cancer, colon cancer, cervical cancer, and melanoma [35, 73–81]. This evidence concerns the gene STK11 and melanoma.